| Trial | Title | Study Record Detail | Phase | Sponsor/Colaborator |
|---|---|---|---|---|
| A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4 | NCT01409135 | I | Agensys, Inc./Seattle Genetics, Inc. | |
| A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4 | NCT02091999 | I | Agensys, Inc./Seattle Genetics, Inc | |
| A Study of Enfortumab Vedotin in Japanese Subjects With Locally Advanced or Metastatic Urothelial Carcinoma | NCT03070990 | I | Agensys, Inc./Seattle Genetics, Inc | |
| A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer (EV-103) | NCT03288545 | Agensys, Inc./Seattle Genetics, Inc | ||
| A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer (EV-201) | NCT03219333 | II | Agensys, Inc./Seattle Genetics, Inc | |
| A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-based Treatment Combinations in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy (MORPHEUS mUC) | NCT03869190 | I/II | Hoffmann-La Roche Collaborators: Forty Seven Inc.,Tesaro Inc., Seattle Genetics and Astellas Inc., Sanofi | |
| A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) | NCT03474107 | III | Agensys, Inc./Seattle Genetics, Inc | |
| An Expanded Access Treatment Protocol of Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma | NCT04136808 | Agensys, Inc./Seattle Genetics, Inc |
Last Editorial Review: December 20, 2019
